Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

By G. Paumgartner, U. Beuers. Hepatology, 2002

741 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/2c0145bddc0341ab2572cc71e186873f5cf9aa4b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Lindor
2. J. Boyer
3. M. Mayo
4. C. Levy
5. C. Bowlus

Citations in the corpus

• Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, background): “The proposed mechanisms of action of UDCA are multiple and include choleretic, cytoprotective, anti-inflammatory, and immunomodulatory properties.(141) A number of studies have shown the benefit of UDCA in this context.”